ES2487633T3 - Métodos y composiciones para prevenir o tratar condiciones oftálmicas - Google Patents

Métodos y composiciones para prevenir o tratar condiciones oftálmicas Download PDF

Info

Publication number
ES2487633T3
ES2487633T3 ES10812524.6T ES10812524T ES2487633T3 ES 2487633 T3 ES2487633 T3 ES 2487633T3 ES 10812524 T ES10812524 T ES 10812524T ES 2487633 T3 ES2487633 T3 ES 2487633T3
Authority
ES
Spain
Prior art keywords
arg
dmt
phe
lys
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10812524.6T
Other languages
English (en)
Inventor
Liping Liu
Shibo Tang
Xiaoling Liang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Peptides International Inc
Original Assignee
Stealth Peptides International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International Inc filed Critical Stealth Peptides International Inc
Application granted granted Critical
Publication of ES2487633T3 publication Critical patent/ES2487633T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un péptido representado por la fórmula D-Arg-2'6'-Dmt-Lys-Phe-NH2 o Phe-D-Arg- Phe-Lys-NH2 para utilizar en el tratamiento o prevención de una condición oftalmológica en donde la condición oftalmológica se selecciona del grupo que consiste de: retinitis pigmentosa, neovascularización coroidea, y retinopatía inducida por el oxígeno.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
E10812524
30-07-2014
TABLA 5. Análogos de péptidos con Actividad Mu-Opioide
Posición del Aminoácido 1
Posición del Aminoácido 2 Posición del Aminoácido 3 Posición del Aminoácido 4 Modificación terminal C
Tyr
D-Arg Phe Lys NH2
Tyr
D-Arg Phe Orn NH2
Tyr
D-Arg Phe Dab NH2
Tyr
D-Arg Phe Dap NH2
2’6’Dmt
D-Arg Phe Lys NH2
2’6’Dmt
D-Arg Phe Lys-NH(CH2)2-NH-dns NH2
2’6’Dmt
D-Arg Phe Lys-NH(CH2)2-NH-atn NH2
2’6’Dmt
D-Arg Phe dnsLys NH2
2’6’Dmt
D-Cit Phe Lys NH2
2’6’Dmt
D-Cit Phe Ahp NH2
2’6’Dmt
D-Arg Phe Orn NH2
2’6’Dmt
D-Arg Phe Dab NH2
2’6’Dmt
D-Arg Phe Dap NH2
2’6’Dmt
D-Arg Phe Ahp(ácido 2aminoheptanoico) NH2
Bio-2’6’Dmt
D-Arg Phe Lys NH2
3’5’Dmt
D-Arg Phe Lys NH2
3’5’Dmt
D-Arg Phe Orn NH2
3’5’Dmt
D-Arg Phe Dab NH2
3’5’Dmt
D-Arg Phe Dap NH2
Tyr
D-Arg Tyr Lys NH2
Tyr
D-Arg Tyr Orn NH2
Tyr
D-Arg Tyr Dab NH2
Tyr
D-Arg Tyr Dap NH2
2’6’Dmt
D-Arg Tyr Lys NH2
2’6’Dmt
D-Arg Tyr Orn NH2
2’6’Dmt
D-Arg Tyr Dab NH2
16
E10812524
30-07-2014
2’6’Dmt
D-Arg Tyr Dap NH2
2’6’Dmt
D-Arg 2’6’Dmt Lys NH2
2’6’Dmt
D-Arg 2’6’Dmt Orn NH2
2’6’Dmt
D-Arg 2’6’Dmt Dab NH2
2’6’Dmt
D-Arg 2’6’Dmt Dap NH2
3’5’Dmt
D-Arg 3’5’Dmt Arg NH2
3’5’Dmt
D-Arg 3’5’Dmt Lys NH2
3’5’Dmt
D-Arg 3’5’Dmt Orn NH2
3’5’Dmt
D-Arg 3’5’Dmt Dab NH2
Tyr
D-Lys Phe Dap NH2
Tyr
D-Lys Phe Arg NH2
Tyr
D-Lys Phe Lys NH2
Tyr
D-Lys Phe Orn NH2
2’6’Dmt
D-Lys Phe Dab NH2
2’6’Dmt
D-Lys Phe Dap NH2
2’6’Dmt
D-Lys Phe Arg NH2
2’6’Dmt
D-Lys Phe Lys NH2
3’5’Dmt
D-Lys Phe Orn NH2
3’5’Dmt
D-Lys Phe Dab NH2
3’5’Dmt
D-Lys Phe Dap NH2
3’5’Dmt
D-Lys Phe Arg NH2
Tyr
D-Lys Tyr Lys NH2
Tyr
D-Lys Tyr Orn NH2
Tyr
D-Lys Tyr Dab NH2
Tyr
D-Lys Tyr Dap NH2
2’6’Dmt
D-Lys Tvr Lys NH2
2’6’Dmt
D-Lys Tyr Orn NH2
2’6’Dmt
D-Lys Tyr Dab NH2
2’6’Dmt
D-Lys Tyr Dap NH2
17
E10812524
30-07-2014
2’6’Dmt
D-Lys 2’6’Dmt Lys NH2
2’6’Dmt
D-Lys 2’6’Dmt Orn NH2
2’6’Dmt
D-Lys 2’6’Dmt Dab NH2
2’6’Dmt
D-Lys 2’6’Dmt Dap NH2
2’6’Dmt
D-Arg Phe dnsDap NH2
2’6’Dmt
D-Arg Phe atnDap NH2
3’5’Dmt
D-Lys 3’5’Dmt Lys NH2
3’5’Dmt
D-Lys 3’5’Dmt Orn NH2
3’5’Dmt
D-Lys 3’5’Dmt Dab NH2
3’5’Dmt
D-Lys 3’5’Dmt Dap NH2
Tyr
D-Lys Phe Arg NH2
Tyr
D-Orn Phe Arg NH2
Tyr
D-Dab Phe Arg NH2
Tyr
D-Dap Phe Arg NH2
2’6’Dmt
D-Arg Phe Arg NH2
2’6’Dmt
D-Lvs Phe Arg NH2
2’6’Dmt
D-Orn Phe Arg NH2
2’6’Dmt
D-Dab Phe Arg NH2
3’5’Dmt
D-Dap Phe Arg NH2
3’5’Dmt
D-Arg Phe Arg NH2
3’5’Dmt
D-Lys Phe Arg NH2
3’5’Dmt
D-Orn Phe Arg NH2
Tyr
D-Lys Tyr Arg NH2
Tyr
D-Orn Tyr Arg NH2
Tyr
D-Dab Tyr Arg NH2
Tyr
D-Dap Tyr Arg NH2
2’6’Dmt
D-Arg 2’6’Dmt Arg NH2
2’6’Dmt
D-Lys 2’6’Dmt Arg NH2
2’6’Dmt
D-Orn 2’6’Dmt Arg NH2
18
E10812524
30-07-2014
2’6’Dmt
D-Dab 2’6’Dmt Arg NH2
3’5’Dmt
D-Dap 3’5’Dmt Arg NH2
3’5’Dmt
D-Arg 3’5’Dmt Arg NH2
3’5’Dmt
D-Lys 3’5’Dmt Arg NH2
3’5’Dmt
D-Orn 3’5’Dmt Arg NH2
Mmt
D-Arg Phe Lys NH2
Mmt
D-Arg Phe Orn NH2
Mmt
D-Arg Phe Dab NH2
Mmt
D-Arg Phe Dap NH2
Tmt
D-Arg Phe Lys NH2
Tmt
D-Arg Phe Orn NH2
Tmt
D-Arg Phe Dab NH2
Tmt
D-Arg Phe Dap NH2
Hmt
D-Arg Phe Lys NH2
Hmt
D-Arg Phe Orn NH2
Hmt
D-Arg Phe Dab NH2
Hmt
D-Arg Phe Dap NH2
Mmt
D-Lys Phe Lys NH2
Mmt
D-Lys Phe Orn NH2
Mmt
D-Lys Phe Dab NH2
Mmt
D-Lys Phe Dap NH2
Mmt
D-Lys Phe Arg NH2
Tmt
D-Lys Phe Lys NH2
Tmt
D-Lys Phe Orn NH2
Tmt
D-Lys Phe Dab NH2
Tmt
D-Lys Phe Dap NH2
Tmt
D-Lys Phe Arg NH2
Hmt
D-Lys Phe Lys NH2
Hmt
D-Lys Phe Orn NH2
19
E10812524
30-07-2014
Hmt
D-Lys Phe Dab NH2
Hmt
D-Lys Phe Dap NH2
Hmt
D-Lys Phe Arg NH2
Mmt
D-Lys Phe Arg NH2
Mmt
D-Orn Phe Arg NH2
Mmt
D-Dab Phe Arg NH2
Mmt
D-Dap Phe Arg NH2
Mmt
D-Arg Phe Arg NH2
Tmt
D-Lys Phe Arg NH2
Tmt
D-Orn Phe Arg NH2
Tmt
D-Dab Phe Arg NH2
Tmt
D-Dap Phe Arg NH2
Tmt
D-Arg Phe Arg NH2
Hmt
D-Lys Phe Arg NH2
Hmt
D-Orn Phe Arg NH2
Hmt
D-Dab Phe Arg NH2
Hmt
D-Dap Phe Arg NH2
Hmt
D-Arg Phe Arg NH2
Dab = diaminobutírico Dap = ácido diaminopropiónico Dmt = dimetiltirosina Mmt = 2’-metiltirosina Tmt = N, 2’,6’-trimetiltirosina Hmt = 2’-hidroxi,6’-metiltirosina dnsDap = ácido β-dansil-L-α, β -diaminopropiónico atnDap = ácido β-antraniloil-L-α, β-diaminopropiónico Bio = biotina
Ejemplos de otros péptidos catiónicos aromáticos que no activan los receptores mu-opioides incluyen, pero no se limitan a, los péptidos catiónicos aromáticos mostrados en la Tabla 6.
20
E10812524
30-07-2014
TABLA 6. Análogos de péptidos Carentes de Actividad Mu-Opioide
Posición del Aminoácido 1
Posición del Aminoácido 2 Posición del Aminoácido 3 Posición del Aminoácido 4 Modificación del Terminal C
D-Arg
Dmt Lys Phe NH2
D-Arg
Dmt Phe Lys NH2
D-Arg
Phe Lys Dmt NH2
D-Arg
Phe Dmt Lys NH2
D-Arg
Lys Dmt Phe NH2
D-Arg
Lys Phe Dmt NH2
Phe
Lys Dmt D-Arg NH2
Phe
Lys D-Arg Dmt NH2
Phe
D-Arg Phe Lys NH2
Phe
D-Arg Dmt Lys NH2
Phe
D-Arg Lys Dmt NH2
Phe
Dmt D-Arg Lys NH2
Phe
Dmt Lys D-Arg NH2
Lys
Phe D-Arg Dmt NH2
Lys
Phe Dmt D-Arg NH2
Lys
Dmt D-Arg Phe NH2
Lys
Dmt Phe D-Arg NH2
Lys
D-Arg Phe Dmt NH2
Lys
D-Arg Dmt Phe NH2
D-Arg
Dmt D-Arg Phe NH2
D-Arg
Dmt D-Arg Dmt NH2
D-Arg
Dmt D-Arg Tyr NH2
D-Arg
Dmt D-Arg Trp NH2
Trp
D-Arg Phe Lys NH2
Trp
D-Arg Tyr Lys NH2
Trp
D-Arg Trp Lys NH2
Trp
D-Arg Dmt Lys NH2
21
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
E10812524
30-07-2014
TABLA 8. Horario Terapéutico -Modelo HFD/STZ
Duración
Objetivo Grupos Diabéticos (A,B,C,D,E,F) Grupo Control (G)
1ª Semana
Aclimatación Alimentación Normal de Rata
2ª -7ª Semana
Manipulación de la Dieta Dieta Alta en Grasa Alimentación Normal de Rata
Final de 7ª Semana
Inyección STZ STZ 30 mg/kg, i.p., una vez Solución reguladora de citrato
8ª -27 Semana
Inducción de Diabetes Dieta alta en grasa hasta la semana 21, luego se cambia a alimentación normal de rata Alimentación Normal de Rata
Semana 28 -37
Tratamiento Peptídico Tratamiento Peptídico (ver Tabla 7) Grupo G: 2 mL/kg, s.c.
Semana 38
Muestras de sangre y orina recolectadas a las 24h, y órganos vitales recolectados
TABLA 9. Grupos de Tratamiento -Modelo STZ
Grupo
Número de Ratas Modelo Tratamiento Dosificación y Ruta
A
11 Diabetes SS-31 10 mg/kg s.c
B
11 Diabetes SS-20 10 mg/kg s.c.
C
10 Diabetes Solución salina Vol. igual s.c.
D
10 Normal Solución salina Vol. igual s.c.

TABLA 10. Horario Terapéutico -Modelo STZ
Duración
Objetivo Grupos Diabéticos (A,B,C) Grupo Control (D)
1ª y 3ª Semana
Aclimatación Alimentación Normal de Rata
Final de 3ª Semana
Inyección STZ STZ 30 mg/kg, i.p., una vez Solución reguladora de citrato
4ª -18ª Semana
Inducción de Complicaciones Diabéticas Alimentación Normal de Rata
Semana 19 -19
Tratamiento Peptídico Tratamiento Peptídico (ver Tabla 9) Grupo D: 2 mL/kg, s.c.
Semana 29
Muestras de sangre y orina recolectadas a las 24h, y órganos vitales recolectados
33
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31

Claims (1)

  1. imagen1
ES10812524.6T 2009-08-24 2010-08-23 Métodos y composiciones para prevenir o tratar condiciones oftálmicas Active ES2487633T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US23644009P 2009-08-24 2009-08-24
US236440P 2009-08-24
US23774509P 2009-08-28 2009-08-28
US237745P 2009-08-28
US34847010P 2010-05-26 2010-05-26
US348470P 2010-05-26
PCT/US2010/046338 WO2011025734A1 (en) 2009-08-24 2010-08-23 Methods and compositions for preventing or treating ophthalmic conditions

Publications (1)

Publication Number Publication Date
ES2487633T3 true ES2487633T3 (es) 2014-08-22

Family

ID=43628336

Family Applications (3)

Application Number Title Priority Date Filing Date
ES23194389T Active ES3036317T3 (en) 2009-08-24 2010-08-23 Peptide for use in preventing or treating macular degeneration
ES20156769T Active ES2964555T3 (es) 2009-08-24 2010-08-23 Péptido para uso en la prevención o tratamiento de la degeneración macular
ES10812524.6T Active ES2487633T3 (es) 2009-08-24 2010-08-23 Métodos y composiciones para prevenir o tratar condiciones oftálmicas

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES23194389T Active ES3036317T3 (en) 2009-08-24 2010-08-23 Peptide for use in preventing or treating macular degeneration
ES20156769T Active ES2964555T3 (es) 2009-08-24 2010-08-23 Péptido para uso en la prevención o tratamiento de la degeneración macular

Country Status (17)

Country Link
US (8) US8470784B2 (es)
EP (18) EP3338788A1 (es)
JP (8) JP6120399B2 (es)
CN (3) CN105056206A (es)
CA (1) CA2772094C (es)
DK (2) DK2470191T3 (es)
ES (3) ES3036317T3 (es)
FI (1) FI3708178T3 (es)
HK (4) HK1204958A1 (es)
HR (1) HRP20231277T1 (es)
HU (1) HUE064800T2 (es)
LT (1) LT3708178T (es)
PL (2) PL3708178T3 (es)
PT (2) PT2470191E (es)
SI (2) SI3708178T1 (es)
SM (1) SMT202300433T1 (es)
WO (1) WO2011025734A1 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9164540B2 (en) 2010-10-01 2015-10-20 Z124 Method and apparatus for moving display during a device flip
AU2009295960A1 (en) 2008-09-29 2010-04-01 Cardiaq Valve Technologies, Inc. Heart valve
EP2341871B1 (en) 2008-10-01 2017-03-22 Edwards Lifesciences CardiAQ LLC Delivery system for vascular implant
CA2961053C (en) 2009-04-15 2019-04-30 Edwards Lifesciences Cardiaq Llc Vascular implant and delivery system
SI3708178T1 (sl) 2009-08-24 2024-01-31 Stealth Biotherapeutics Inc. Peptid za uporabo pri preprečevanju ali zdravljenju degeneracije makule
EP2808029A3 (en) * 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
WO2011137363A1 (en) * 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
US8579964B2 (en) 2010-05-05 2013-11-12 Neovasc Inc. Transcatheter mitral valve prosthesis
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
EP3108975A1 (en) * 2011-03-24 2016-12-28 Cornell University Aromatic-cationic peptides and uses of same
US9308087B2 (en) 2011-04-28 2016-04-12 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
US9554897B2 (en) 2011-04-28 2017-01-31 Neovasc Tiara Inc. Methods and apparatus for engaging a valve prosthesis with tissue
CN102327600A (zh) * 2011-09-14 2012-01-25 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防和治疗辐射损伤的rx31肽
US20130076654A1 (en) 2011-09-27 2013-03-28 Imerj LLC Handset states and state diagrams: open, closed transitional and easel
CA2858550A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
HK1204988A1 (en) * 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CA2869080C (en) * 2012-03-30 2020-09-01 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
US9345573B2 (en) 2012-05-30 2016-05-24 Neovasc Tiara Inc. Methods and apparatus for loading a prosthesis onto a delivery system
US10188693B2 (en) * 2012-08-02 2019-01-29 Stealth Biotherapeutics Corp Methods for treatment of atherosclerosis
CA2888899C (en) 2012-10-24 2023-02-21 Japan Innovative Therapeutics, Inc. Use of tryptase inhibitors in the treatment retinopathy of prematurity
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US10793597B2 (en) * 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
US10583002B2 (en) 2013-03-11 2020-03-10 Neovasc Tiara Inc. Prosthetic valve with anti-pivoting mechanism
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9681951B2 (en) 2013-03-14 2017-06-20 Edwards Lifesciences Cardiaq Llc Prosthesis with outer skirt and anchors
US9572665B2 (en) 2013-04-04 2017-02-21 Neovasc Tiara Inc. Methods and apparatus for delivering a prosthetic valve to a beating heart
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US20160193278A1 (en) * 2013-08-01 2016-07-07 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
CA2920735A1 (en) * 2013-08-12 2015-02-19 Stealth Biotherapeutics Corp Combination therapy for the treatment of ischemia-reperfusion injury
CA2928702A1 (en) * 2013-10-25 2015-04-30 Children's Medical Center Corporation Methods of treating or preventing vascular diseases of the retina
CA2932408A1 (en) * 2013-12-02 2015-06-11 Stealth Biotherapeutics Corp Compositions and methods for treating vitiligo
US20160317606A1 (en) * 2014-01-06 2016-11-03 Stealth Bio Therapeutics Corp Methods and compositions for preventing or treating dominant optic atrophy
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
AU2015243261B2 (en) 2014-04-10 2020-06-25 Lankenau Institute For Medical Research Methods and compositions for the treatment of ocular diseases and disorders
WO2015183988A1 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including therapeutic small molecules and uses thereof
US10327946B2 (en) * 2014-12-19 2019-06-25 Kemin Industries, Inc. Intraocular delivery of bioactive molecules using iontophoresis
US10973867B2 (en) 2015-12-30 2021-04-13 Marshall University Research Corporation Compositions and methods for treating retinopathy
WO2017156403A1 (en) * 2016-03-11 2017-09-14 Stealth Biotherapeutics Crystalline salt forms
WO2017177262A1 (en) * 2016-04-11 2017-10-19 University Of Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
BR112020009361A2 (pt) * 2017-11-17 2020-10-13 Cellix Bio Private Limited composto de fórmula i, composição farmacêutica para tratar um distúrbio ocular ou complicações do mesmo, método de síntese de composto, método de tratamento de um distúrbio ocular ou complicações do mesmo em um indivíduo que precisa do mesmo e uso de um composto
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
PL424452A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
US11400070B2 (en) * 2018-05-03 2022-08-02 Alimera Sciences, Inc. Methods of treating retinal diseases
WO2020018455A1 (en) * 2018-07-16 2020-01-23 Stealth Biotherapeutics Corp Compositions and methods for the treatment of traumatic optic neuropathy
US11752175B2 (en) * 2018-09-21 2023-09-12 Cornell University Compositions and methods for glaucoma
US20220096467A1 (en) * 2019-01-12 2022-03-31 Cellix Bio Provate Limited Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof
JP2020174859A (ja) * 2019-04-17 2020-10-29 学校法人日本医科大学 網膜剥離が生じるリスクが低い網膜変性症（ｒｄ）モデルマウスを取得する方法
WO2020214990A1 (en) * 2019-04-17 2020-10-22 Ascidian Therapeutics, Inc. Abca4 cell line and methods of use
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
JP7705106B2 (ja) * 2019-05-28 2025-07-09 ナノ－ネオ リミテッド 網膜症を治療するための組成物及び方法
CN115996742A (zh) * 2020-03-25 2023-04-21 奥夫博医疗创新有限公司 用于青光眼的方法和药剂
WO2022138842A1 (ja) * 2020-12-24 2022-06-30 参天製薬株式会社 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物
US20240197623A1 (en) * 2021-04-07 2024-06-20 Stealth Bio Therapeutics Inc. Silica-based formulations of therapeutic oliogpeptides and peptidomimetics
WO2023069549A1 (en) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023069255A1 (en) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023086873A1 (en) * 2021-11-10 2023-05-19 Reverspah Llc Methods and compositions for treating cancer
CN114099678A (zh) * 2021-11-23 2022-03-01 浙江大学 基于Keap1-Nrf2信号通路的晶状体损伤抑制剂
KR102662922B1 (ko) * 2022-05-31 2024-05-03 주식회사 세네릭스 신규의 d-아미노산 유도체 및 이를 포함하는 약학 조성물
CN117243895A (zh) * 2023-07-13 2023-12-19 河南大学 一种磷脂dspe-peg2000-ss31、负载药物的方法及其抗脑胶质瘤的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
SG64368A1 (en) * 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
EP0747092B1 (en) * 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6268398B1 (en) * 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6503713B1 (en) * 1999-10-04 2003-01-07 University Of Medicine And Dentistry Of New Jersey Methods for identifying RNA binding compounds
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
JP2001270832A (ja) * 2000-03-27 2001-10-02 Ito En Ltd 網膜障害予防剤
ATE496533T1 (de) * 2000-07-18 2011-02-15 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu- opioid rezeptors
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
EP1542664A4 (en) * 2002-08-14 2008-04-16 Med College Georgia Res Inst METHOD AND COMPOSITIONS FOR TREATING MACULA AND RETINA DISEASES
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20060172972A1 (en) 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
JP2004323486A (ja) * 2003-04-30 2004-11-18 National Institute Of Advanced Industrial & Technology 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬
EP3167935B1 (en) * 2003-05-01 2018-07-18 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
US7232824B2 (en) * 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
DK1755616T3 (da) 2004-04-08 2013-11-25 Eye Co Pty Ltd Behandling af ekssudativ retinopati med mineralkortikoider
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
JP4760111B2 (ja) 2005-04-26 2011-08-31 株式会社セガ 映像オブジェクト表現用データ構造生成プログラム、映像オブジェクト表現用データ構造生成方法、映像ソフト開発装置、映像処理プログラム、映像処理方法、映像処理装置、映像オブジェクト表現用データ構造、および、記録媒体
US8088773B2 (en) 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
JP2007043629A (ja) * 2005-06-30 2007-02-15 Sony Corp グラフィック・ユーザ・インタフェース装置と操作入力処理方法及び双方向コミュニケーション装置
EP1904108B1 (en) 2005-07-15 2011-11-30 Chakshu Research, Inc. Ophthalmological formulation comprising methylsulfonylmethane and ciprofloxacin
EP3725324A1 (en) * 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
US20090270315A1 (en) 2005-10-05 2009-10-29 Aqumen Biopharmaceuticals K.K. Method of inhibiting angiogenesis by using ephrin b2
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
TW200744627A (en) 2006-02-21 2007-12-16 Pfizer Prod Inc Methods for the treatment of macular degeneration and related eye conditions
KR20110079922A (ko) * 2006-04-14 2011-07-11 노파르티스 아게 안과 장애 치료를 위한 ｉｌ－1 항체의 용도
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
DE102006042329B4 (de) * 2006-09-01 2008-08-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zum selektiven plasmachemischen Trockenätzen von auf Oberflächen von Silicium-Wafern ausgebildetem Phosphorsilikatglas
JP2010512327A (ja) 2006-12-11 2010-04-22 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 病的血管形成および脈管透過性の処置用の組成物および方法
JP2008195655A (ja) * 2007-02-14 2008-08-28 Kitasato Institute 糖尿病白内障の治療剤
JP2008247898A (ja) * 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2008146721A1 (ja) 2007-05-25 2008-12-04 Santen Pharmaceutical Co., Ltd. 加齢黄斑変性の予防又は治療剤
EP2712620A1 (en) * 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
CN107802821A (zh) * 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
FR2945540B1 (fr) 2009-05-15 2012-06-08 Rhodia Operations Procede de preparation de mousse polyamide et mousse susceptible d'etre obtenue par ce procede
CA2770688C (en) 2009-08-12 2018-06-05 Cornell University Methods for preventing or treating metabolic syndrome
SI3708178T1 (sl) * 2009-08-24 2024-01-31 Stealth Biotherapeutics Inc. Peptid za uporabo pri preprečevanju ali zdravljenju degeneracije makule
CA2787331A1 (en) 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same
EP3332795A1 (en) * 2010-02-26 2018-06-13 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
JP2013532124A (ja) 2010-05-03 2013-08-15 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族系陽イオンペプチド及びその使用
CA2839408A1 (en) 2011-06-14 2012-12-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CA2916492A1 (en) * 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
US20160199437A1 (en) * 2015-01-08 2016-07-14 D. Travis Wilson Therapeutic compositions including iron chelators and uses thereof
US20160228491A1 (en) * 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof

Also Published As

Publication number Publication date
US8470784B2 (en) 2013-06-25
HK1217900A1 (en) 2017-01-27
JP2013502460A (ja) 2013-01-24
US11944662B2 (en) 2024-04-02
JP2016026188A (ja) 2016-02-12
HK1204958A1 (en) 2015-12-11
EP4596049A2 (en) 2025-08-06
LT3708178T (lt) 2023-12-27
EP3318264A1 (en) 2018-05-09
HUE064800T2 (hu) 2024-04-28
JP2017141306A (ja) 2017-08-17
EP3494983A1 (en) 2019-06-12
CN107412722A (zh) 2017-12-01
US20170326197A1 (en) 2017-11-16
CN105056206A (zh) 2015-11-18
US20160058825A1 (en) 2016-03-03
JP2022001609A (ja) 2022-01-06
SI2470191T1 (sl) 2014-08-29
EP2470191A1 (en) 2012-07-04
EP3485896A1 (en) 2019-05-22
EP3150215A1 (en) 2017-04-05
EP3524256A1 (en) 2019-08-14
ES2964555T3 (es) 2024-04-08
JP7642965B2 (ja) 2025-03-11
EP2470191B1 (en) 2014-05-07
HK1247821A1 (zh) 2018-10-05
JP2025181975A (ja) 2025-12-11
ES3036317T3 (en) 2025-09-17
WO2011025734A1 (en) 2011-03-03
EP4302829A3 (en) 2024-03-27
US9023807B2 (en) 2015-05-05
US10188692B2 (en) 2019-01-29
EP2990049A1 (en) 2016-03-02
JP6381737B2 (ja) 2018-08-29
US20230346874A1 (en) 2023-11-02
JP6332757B2 (ja) 2018-05-30
US20230381264A1 (en) 2023-11-30
US20210154259A1 (en) 2021-05-27
EP3708178B1 (en) 2023-10-04
US20110177047A1 (en) 2011-07-21
EP3708178A1 (en) 2020-09-16
EP2470191A4 (en) 2013-04-17
PT3708178T (pt) 2023-11-16
JP2023179733A (ja) 2023-12-19
SI3708178T1 (sl) 2024-01-31
US20200061147A1 (en) 2020-02-27
US9549963B2 (en) 2017-01-24
EP3292868A1 (en) 2018-03-14
HK1172833A1 (en) 2013-05-03
US11612633B2 (en) 2023-03-28
EP3175862A1 (en) 2017-06-07
JP6120399B2 (ja) 2017-04-26
EP2957291A1 (en) 2015-12-23
EP3124036A1 (en) 2017-02-01
PL3708178T3 (pl) 2024-05-13
HRP20231277T1 (hr) 2024-02-02
DK2470191T3 (da) 2014-07-07
EP3338788A1 (en) 2018-06-27
EP2826487A1 (en) 2015-01-21
EP4302829A2 (en) 2024-01-10
PT2470191E (pt) 2014-06-12
EP2962695A1 (en) 2016-01-06
CA2772094A1 (en) 2011-03-03
HK1206258A1 (en) 2016-01-08
EP2813235A1 (en) 2014-12-17
SMT202300433T1 (it) 2024-01-10
EP4596049A3 (en) 2025-08-13
CN102625709A (zh) 2012-08-01
PL2470191T3 (pl) 2014-09-30
US20140044689A1 (en) 2014-02-13
JP2018162329A (ja) 2018-10-18
EP4302829B1 (en) 2025-05-21
DK3708178T3 (da) 2023-11-13
FI3708178T3 (fi) 2023-11-09
CA2772094C (en) 2018-04-03
JP2020128431A (ja) 2020-08-27

Similar Documents

Publication Publication Date Title
ES2576746T3 (es) Métodos para prevenir o tratar síndrome metabólico
RU2500685C2 (ru) Синтетические пептидные амиды
TWI374030B (en) Use of melanocortins to treat insulin sensitivity
TW487711B (en) Conjugates of lipophilic moieties and peptides
JPH10509737A (ja) サイトカイン調節剤およびサイトカインレベルの変化に関連する病状および状態における使用方法
CN109745549A (zh) Glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
CN110755599A (zh) 用于治疗和预防良性前列腺增生的组合物
EP4302829A2 (en) Peptide for use in preventing or treating macular degeneration
CN106866814A (zh) Dpp‑4抑制剂
JP3668950B2 (ja) ペプチドと、その合成方法と、それをベースにした医薬品
US20180042983A1 (en) Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof, and methods of using the same
CN110945010A (zh) 肽组合物和相关方法
WO2017101144A1 (zh) 脂肪组织靶向多肽及其制备方法和应用
KR20180004752A (ko) 신규 펩티드 및 이를 포함한 조성물
TWI305778B (en) Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use
NO317919B1 (no) Tri-, tetra-, penta-, og polypeptider samt deres anvendelse for fremstilling av et farmasoytisk preparat til behandling av depresjon
JP2022513305A (ja) アディポネクチン由来ペプチドを含む発毛促進用組成物
WO2016062234A1 (zh) 八肽修饰的地塞米松,其制备,纳米结构和应用
CA2992971C (en) Peptides useful for treating cancer
CA2581564C (en) Compounds that modulate trh actions
AU2024251399A1 (en) κ OPIOID RECEPTOR AGONIST AND USE THEREOF
WO2009094137A2 (en) Urotensin-ii agonists
HK1228253B (en) Composition for treating and preventing benign prostatic hyperplasia
HK1242194A1 (en) Methods for preventing or treating metabolic syndrome
HK1174844A (en) Methods for preventing or treating metabolic syndrome